Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

381 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.
Fasching PA, Jud SM, Hauschild M, Kümmel S, Schütte M, Warm M, Hanf V, Grab D, Krocker J, Stickeler E, Kreienberg R, Müller T, Kühn T, Wolf C, Kahlert S, Paepke S, Berghorn M, Muth M, Baier M, Wackwitz B, Schulz-Wendtland R, Beckmann MW, Lux MP. Fasching PA, et al. Among authors: kreienberg r. BMC Cancer. 2014 Feb 5;14:66. doi: 10.1186/1471-2407-14-66. BMC Cancer. 2014. PMID: 24499441 Free PMC article. Clinical Trial.
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Lux MP, Wöckel A, Benedict A, Buchholz S, Kreif N, Harbeck N, Kreienberg R, Kaufmann M, Beckmann MW, Jonat W, Hadji P, Distler W, Raab G, Tesch H, Weyers G, Possinger K, Schneeweiss A. Lux MP, et al. Among authors: kreienberg r. Onkologie. 2010;33(4):155-66. doi: 10.1159/000286233. Epub 2010 Mar 19. Onkologie. 2010. PMID: 20389141 Clinical Trial.
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S. Untch M, et al. Among authors: kreienberg r. J Clin Oncol. 2011 Sep 1;29(25):3351-7. doi: 10.1200/JCO.2010.31.4930. Epub 2011 Jul 25. J Clin Oncol. 2011. PMID: 21788566 Clinical Trial.
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups. von Minckwitz G, et al. Among authors: kreienberg r. N Engl J Med. 2012 Jan 26;366(4):299-309. doi: 10.1056/NEJMoa1111065. N Engl J Med. 2012. PMID: 22276820 Free article. Clinical Trial.
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
Harbeck N, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba BJ, Waldenmaier D, Dorn J, Warm M, Scholz M, Untch M, de Wit M, Barinoff J, Lück HJ, Harter P, Augustin D, Harnett P, Beckmann MW, Al-Batran SE; PELICAN Investigators. Harbeck N, et al. Among authors: kreienberg r. Breast Cancer Res Treat. 2017 Jan;161(1):63-72. doi: 10.1007/s10549-016-4033-3. Epub 2016 Oct 31. Breast Cancer Res Treat. 2017. PMID: 27798749 Free PMC article. Clinical Trial.
381 results